Skip to main content
Premium Trial:

Request an Annual Quote

Celera Names Milsten General Counsel, Invitrogen Announces Board Members, Expression Analysis Hires New CFO, and More

NEW YORK (GenomeWeb News) - Celera has tapped Scott Milsten to be VP, general counsel, and corporate secretary. Milsten previously was deputy general counsel for Gen-Probe, and before that he was a corporate attorney with Latham & Watkins.

Signature Genomic Laboratories has named Allen Lamb to be laboratory director. Lamb formerly was a medical director in the cytogenetics lab at the University of Utah’s ARUP Labs, and he is an associate professor at the University’s School of Medicine. He also is a founding fellow of the American College of Medical Genetics.

PerkinElmer Life and Analytical Sciences has appointed Martina Bielefeld-Sévigny to serve as VP and general manager of drug discovery and research reagents. Bielefeld-Sévigny previously was director of molecular pharmacology in PerkinElmer’s Bio-discovery reagents business, and she led the company’s Center of Excellence in Montreal. She also previously served as director of process development at DSM Biologics, and she worked at Pharmacia Biotech.

Invitrogen has added three members from merger partner Applied Biosystems’ board of directors to serve on the board of the new company, which will be called Life Technologies. These directors include George Adam, who is chairman of Recondo Technology; Arnold Levine, who is a professor at the Institute for Advanced Study; and William Longfield, who is a retired chairman and chief executive officer of CR Bard.

Expression Analysis has hired Eric Setzer to be chief financial officer, and it has named Gary Boch senior director of sales. Seltzer previously was CFO at Kolis Scientific, and Boch was national director of industrial markets at Amaxa.

Jonathan Sheridan will succeed John Elling as CEO and president of Integrated Genomics. Elling will continue to serve as chairman of the company’s board of directors. Sheridan previously was VP of commercial operations at HTG, and he served in other senior roles at PerkinElmer Life and Analytical Sciences, Beckman Coulter, Genomica, and Monsanto.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.